FMP
NASDAQ
1.05 USD
-0.05 (-4.76%)
Dr. Angelos M. Stergiou M.D., ScD h.c.
Healthcare
Biotechnology
https://www.sellaslifesciences.com
NASDAQ
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck...
0001390478
US81642T2096
81642T209
Times Square Tower
646 200 5278
US
17
Mar 12, 2008
0001390478
NASDAQ
Biotechnology
Healthcare
81642T209
US81642T2096
US
1.05
2.35
1.31M
44.38M
-
0.5-1.91
0.66
-
-
-
-
-0.69
-
https://www.sellaslifesciences.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.